NewTimeSpace丨BioRay Biopharmaceutical, China's Leading Autoimmune Disease Company, Files for Hong Kong IPO
BioRay Biopharmaceutical recently submitted its listing application to the Hong Kong Stock Exchange. According to Frost & Sullivan, the company has ranked first among Chinese pharmaceutical companies by autoimmune disease biologics revenue for two consecutive years since 2023. The prospectus shows it recorded revenue of RMB 1.623 billion and net profit of RMB 91 million in 2024, with a gross margin of 79.2%.
Zhejiang BioRay Biopharmaceutical Co., Ltd. (hereinafter referred to as "BioRay Biopharmaceutical") recently submitted its prospectus to the Hong Kong Stock Exchange, seeking a listing on the Main Board with Huatai International and J.P. Morgan as joint sponsors.
Tags：
- AI apps lead the charge—CSOP STAR 50 Index ETF (03109.HK) surges nearly 4%.
- SOL is closing in on US$145, pushing Chinaamc Solana Etf (03460.HK) toward a fourth straight session of gains.
- ETH peaked at 3,398, sending Pando Ethereum ETF (03085.HK) up 6.64% in early trade.
- Marketing Market Size Expected to See High Growth,GF CSI Media Index ETF(512980) Rises Nearly 5%, Aiming for 10th Consecutive Gain
- Healthcare Sector Poised for "Davis Double Play",Guotai CSI Medical Service ETF (159828) Surges Nearly 3% in Morning Trading, Aiming for Fifth Consecutive Gain
